Asclepix.com

AsclepiX Therapeutics is dedicated to transforming the treatment of ocular diseases through the rapid clinical development of innovative therapies that empower patients and their families globally. The company's lead candidate, AXT107, targets retinal vascular diseases by inhibiting specific growth factor receptors and stabilizing vascular structures, aiming to improve vision and reduce treatment frequency.

Founded by researchers from the Johns Hopkins University School of Medicine, AsclepiX has evolved into a leader in biomedical and pharmaceutical fields, focusing on translating scientific discoveries into effective therapies. The company fosters a culture of curiosity, creativity, and operational excellence, which drives its commitment to addressing significant unmet healthcare needs worldwide.

Generated from the website